February 27, 2024
The FDA has approved two medications for the treatment of eosinophilic esophagitis (EoE)—the first oral medication tailored for adults and the exclusive therapeutic option for children. Evan Dellon, MD, MPH, internationally known for his work with EoE, and colleagues continue to focus on optimizing usage for effective, personalized outcomes.
February 25, 2024
Stage one results from the OUtMATCH clinical trial, published in the New England Journal of Medicine, show that a monoclonal antibody, omalizumab, increased the amount of peanut, tree nuts, egg, milk and wheat that multi-food allergic children as young as age one could consume without an allergic reaction. Edwin Kim, MD, Corinne Keet, MD, PhD, and Mike Kulis, PhD, are contributing authors.
February 13, 2024
Cynthia L. Gay, MD, MPH, associate professor of infectious diseases, and David Margolis, MD, the Sarah Kenan Distinguished Professor of Medicine, Microbiology & Immunology, and Epidemiology in the UNC School of Medicine, published results of a clinical trial showing that vorinostat and immunotherapy may modestly shrink the latent HIV reservoir.
November 7, 2023
UNC Health is the only academic healthcare system in North Carolina and the South participating in the randomized trial, which aims to assess the safety and efficacy of a combination immunotherapy for newly diagnosed glioblastoma patients.
July 31, 2023
Researchers in UNC School of Medicine’s Department of Otolaryngology/Head and Neck Surgery and collaborators at Yale Cancer Center and ECOG-ACRIN Cancer Research Group have identified two subtypes of human papillomavirus positive head and neck cancers, giving them a better glimpse into why some patients respond better to treatment than others.
July 6, 2023
Washington, N.C man with squamous cell carcinoma of the tongue experiences positive life-changing results after participating in an induction therapy clinical trial at the UNC School of Medicine.
May 12, 2023
Jennifer S. Smith, PhD, at the UNC Gillings School of Global Public Health, UNC School of Medicine, and UNC Lineberger Comprehensive Cancer Center, led the phase 3 controlled trial, which showed that self-collection kits and scheduling assistance are key for reaching these populations and preventing cervical cancer.
May 11, 2023
The study, called EPITOPE, led by senior author A. Wesley Burks, MD, CEO of UNC Health and dean of the UNC School of Medicine, and contributing author Edwin Kim, MD, MS, associate professor of pediatrics in the Division of Pediatric Allergy and Immunology at the UNC School of Medicine, shows superior results in desensitizing children to peanuts. Results were recently published in the New England Journal of Medicine.
April 7, 2023
Dominique Higgins, MD, PhD, led research into how a specialized diet can induce a new type of programmed cell death to help kill brain tumor cells.
April 3, 2023
Michael Kappelman, MD, MPH, was the lead PI on the clinical trial, which followed nearly 300 children with Crohn’s to evaluate how their conditions changed in response to anti-TNF biologic treatments alone or in combination with a second immune suppressive medication.
February 27, 2023
A four-year clinical trial led by Edwin Kim, MD, at the UNC School of Medicine, has found that an increased dosage of a unique type of peanut allergy immunotherapy continues to show promise for children.
November 21, 2022
A new glioblastoma treatment from Northwest Biotherapeutics improved outcomes for many patients in a phase 3 clinical study, according to a study published in JAMA Oncology. Matt Ewend, MD, in the UNC Department of Neurosurgery and at UNC Lineberger, led the trial site at the N.C. Basnight Cancer Hospital.